Hypoxia-Inducible Factor
A major therapeutic platform at FibroGen is based on using small molecules to selectively harness and direct certain beneficial aspects of the body's hypoxia-inducible factor (HIF) system for clinical benefit.
HIF Biology
HIF is an important regulatory protein that orchestrates the body's emergency response system to hypoxia (inadequate levels of cellular oxygen). When activated, HIF coordinates expression of genes that mediate cellular and physiological responses to protect against tissue damage and cell death and to restore oxygen balance. Read more
HIF-PHI Therapy
FibroGen is engaged in the discovery and development of novel HIF prolyl hydroxylase inhibitors (HIF-PHI), which research has shown can be used to selectively modulate the HIF system for potential therapeutic benefit in a wide range of clinical settings. Selective pharmacological modulation of the HIF system using HIF-PHI is possible due in part to the system's inherent complexity and multiple points of control. Read more
Development Programs
FibroGen has advanced three unique HIF-PHI into human studies. These HIF-PHI are the first clinical candidates chosen from a large proprietary collection of HIF-PHI, which FibroGen continues to optimize, and from which the most promising molecules will be selected for further development.
FibroGen has development programs in the following areas:
